The outbreak of COVID-19 has posed several new challenges to diabetes care and has also provided an opportunity for transforming the treatment of diabetic patients. Lockdowns caused by the coronavirus disease have up-turned the lives of people everywhere. Yet, for those living with diabetes, the movement restrictions have raised a whole series of extra questions: how can they seek advice; how can their health be monitored; and how can they continue to manage their condition?
Because of the containment and mitigation measures, people with diabetes found themselves without essential services. This has been disrupting the practices for preventing diabetes-related complications. However, Government bodies and Healthcare professionals and those who support people with diabetes have rallied really well during the lockdown to find innovative ways to help.
People with diabetes most vulnerable during COVID-19
Some of the issues and challenges that have emerged include the reported high incidence of COVID-19 infections among persons with diabetes resulting in a higher number of ICU admissions and higher mortality reported in them. The increased predisposition of patients with diabetes to COVID-19 infections is believed to be related to a compromised innate immunity that accompanies uncontrolled diabetes. The situation would be worse if there are other co-morbidities such as hypertension, chronic kidney disease, or coronary artery disease which often co-exist with diabetes and are also associated with more aggressive COVID-19 infections.
Furthermore, because people with diabetes represent a fragile population that is at an increased risk of mortality from COVID-19, it is recommended to avoid unnecessary diabetes-related hospital admissions to reduce the risk of COVID-19 exposure in the hospital.
Bu hikaye BioSpectrum Asia dergisinin November 2020 sayısından alınmıştır.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Giriş Yap
Bu hikaye BioSpectrum Asia dergisinin November 2020 sayısından alınmıştır.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Giriş Yap
Promega unveils GloMax Galaxy Bioluminescence Imager for illuminating protein dynamics in real time
US-based Promega Corporation, a life-sciences research partner dedicated to providing intuitive tools that empower scientists to innovate, has unveiled the new GloMax Galaxy Bioluminescence Imager.
Singleron and Bioscreen to enhance access to single cell multi-omics solutions for Indian researchers
Singleron Biotechnologies, a leading innovator in single cell multi-omics solutions, has announced a strategic partnership with Bioscreen, a renowned distributor of advanced life science products in India.
Eppendorf brings CO2 incubator shaker with integrated 180 °C sterilisation routine
Eppendorf has announced the launch of a CO2 incubator shaker with integrated 180 °C sterilisation routine.
Waters introduces new bioseparations tools to improve development of RNA-based vaccines using LC-MS analysis
US-based Waters Corporation has introduced a comprehensive set of sample preparation enzymes, reagents, and waters_connect software that simplify sequence and modification confirmation of large molecule RNA therapeutics using liquid chromatography-mass spectrometry (LCMS) analysis.
Singapore designs novel gene therapy offering hope for epilepsy patients
Researchers from the Yong Loo Lin School of Medicine, National University of Singapore are working on a therapy that holds potential in treating patients with epilepsy, a neurological disorder defined by recurring seizures due to abnormal brain activity.
Spider venom heart drug moves to clinical trials in Australia
A University of Queensland (UQ)-led project in Australia to develop the first-ever drug to treat heart attack and protect donor hearts will move to human clinical trials, after receiving $17.8 million in funding from the Medical Research Future Fund (MRFF).
India develops portable ultrasound scanner for sports injury diagnosis
A team of researchers at the Indian Institute of Technology Madras (IIT-M) has developed an indigenous portable Point-of-CareUltrasound (POCUS) Scanner for sports injury diagnosis and management.
Integris appoints medtech veteran Probir Das as new CEO
Integris Healthcare, a global diversified medical technology company, has announced the appointment of Probir Das as Chief Executive Officer (CEO). He will join effective November 2024 and will be based in New Delhi.
Clarity Pharma promotes Michelle Parker to CEO
Australia-based Clarity Pharmaceuticals has announced the appointment of Michelle Parker as Chief Executive Officer (CEO), effective from October 11, 2024.
Dr Makoto Sugita steps in as President of Nxera Pharma Japan
Nxera Pharma Co., formerly known as Sosei Group or Sosei Heptares, has announced the appointment of Dr Makoto Sugita, as President of Nxera Pharma Japan, and Executive Officer, Executive Vice President and Chief Medical Officer (CMO) of Nxera Pharma.
